Kenneth Nelson Wills

Title: Kenneth Nelson Wills: Innovator in Cancer Vaccine Development

Introduction

Kenneth Nelson Wills is a notable inventor based in Carlsbad, CA (US). He has made significant contributions to the field of cancer research, particularly in the development of innovative cancer vaccines. With a total of 3 patents to his name, Wills has focused on creating immunogenic therapies that aim to improve cancer treatment outcomes.

Latest Patents

Wills' latest patents revolve around cancer vaccines. The present disclosure provides (i) isolated immunogenic TAA polypeptides, including immunogenic MUC1 polypeptides, immunogenic MSLN polypeptides, and immunogenic TERT polypeptides. It also includes (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to the uses of the polypeptides, nucleic acid molecules, and compositions.

Career Highlights

Throughout his career, Kenneth Wills has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Pfizer Corporation and Trieza Therapeutics, Inc. His work in these organizations has contributed to advancements in medical research and therapeutic development.

Collaborations

Wills has collaborated with several professionals in his field, including Joseph John Binder and Paul Jason Cockle. These collaborations have likely enhanced his research and innovation efforts in cancer vaccine development.

Conclusion

Kenneth Nelson Wills is a distinguished inventor whose work in cancer vaccines has the potential to make a significant impact on cancer treatment. His innovative approaches and collaborations reflect his commitment to advancing medical science.